Cargando…

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease

PURPOSE: The aim of this study was to investigate real-world patient characteristics, medication use, and health care resource utilization (HCRU) and costs among patients with clinical atherosclerotic cardiovascular disease (ASCVD) as defined by 2013 American College of Cardiology/American Heart Ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Power, Thomas P, Ke, Xuehua, Zhao, Zhenxiang, Bonine, Nicole Gidaya, Cziraky, Mark J, Grabner, Michael, Barron, John J, Quimbo, Ralph, Vangerow, Burkhard, Toth, Peter P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804267/ https://www.ncbi.nlm.nih.gov/pubmed/29440909 http://dx.doi.org/10.2147/VHRM.S146266

Ejemplares similares

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
por: Toth, Peter P, et al.
Publicado: (2012)

Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States
por: Bonine, Nicole Gidaya, et al.
Publicado: (2020)

The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy
por: Thayer, Sarah, et al.
Publicado: (2013)

Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections
por: Lodise, Thomas P., et al.
Publicado: (2019)

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
por: Palli, Swetha Rao, et al.
Publicado: (2015)

Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device
por: Grabner, Michael, et al.
Publicado: (2013)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation
por: Vikulova, Diana N., et al.
Publicado: (2020)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

The SWEET SPOTS study: a real-world interpretation of the 2012 American Diabetes Association Position Statement regarding individualized A1C targets
por: Bieszk, Nella, et al.
Publicado: (2016)

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
por: Sciattella, Paolo, et al.
Publicado: (2021)

Lipid lowering by hydroalcoholic extracts of Amaranthus Caudatus L. induces regression of rabbits atherosclerotic lesions
por: Kabiri, Najmeh, et al.
Publicado: (2011)

The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
por: Daida, Hiroyuki, et al.
Publicado: (2019)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
por: Shaya, Fadia Tohme, et al.
Publicado: (2019)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study
por: Shen, Xian, et al.
Publicado: (2019)

Changes in atherosclerotic plaque composition assessed by MRI in the superficial femoral artery with two years of lipid lowering therapy
por: West, Amy M, et al.
Publicado: (2011)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Explore the Lipid-Lowering and Weight-Reducing Mechanism of Lotus Leaf Based on Network Pharmacology and Molecular Docking
por: Zhou, Guangjiao, et al.
Publicado: (2021)

Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin
por: Ekstrand, Matias, et al.
Publicado: (2015)

Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
por: Citarella, Anna, et al.
Publicado: (2022)

Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making
por: Villines, Todd C, et al.
Publicado: (2020)

The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
por: Xing, R., et al.
Publicado: (2018)

Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease
por: Jafar, Zain, et al.
Publicado: (2020)

Importance of lipid ratios for predicting intracranial atherosclerotic stenosis
por: Yang, Wen-Song, et al.
Publicado: (2020)

Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model
por: Devel, Laurent, et al.
Publicado: (2019)

A Lipid-Structured Model of Atherosclerotic Plaque Macrophages with Lipid-Dependent Kinetics
por: Watson, Michael G., et al.
Publicado: (2023)

Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year
por: Tran, Josephine N., et al.
Publicado: (2016)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting
por: Weng, Wayne, et al.
Publicado: (2020)

Challenges in Resource Utilization for Caregivers of Persons With Dementia: A qualitative Study
por: Turner, Robert, et al.
Publicado: (2021)

Characterization of lipid parameters in diabetic and non-diabetic atherosclerotic patients
por: Ali, Fatima, et al.
Publicado: (2015)

Lipid and protein maps defining arterial layers in atherosclerotic aorta
por: Martin-Lorenzo, Marta, et al.
Publicado: (2015)

Hydrogen Sulfide Abrogates Hemoglobin-Lipid Interaction in Atherosclerotic Lesion
por: Potor, László, et al.
Publicado: (2018)

Resveratrol inhibits lipid accumulation in the intestine of atherosclerotic mice and macrophages
por: Ye, Guozhu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4jlqiu122srf9736cd30o6ecru